- Nexus CGH Gets Scientists 'Back to the Bench'-
EL SEGUNDO, Calif., Oct. 16 /PRNewswire/ -- BioDiscovery, Inc. the pioneering developer of integrated software solutions for microarray-based research, announced today the release of NEXUS CGH version 2, the first commercial software tool that provides easy, fast and powerful platform independent and cross-platform analysis of multiple array based DNA copy number data sets, simultaneously.
NEXUS CGH easily supports large-scale array experiments involving thousands of samples from any platform, including high-density multi-million probe SNP as well as two-color CGH arrays. Its user-friendly interface, allows the researcher to quickly identify potential regions of significant copy number changes in various biological categories and extract a gene list for the smallest region of overlap in the sample set.
"Using NEXUS CGH, my lab has been able to quickly and confidently process large amounts of high-density array CGH data obtained from FFPE tumor samples to identify important chromosomal regions," said Dr. Jeff Gregg head of Molecular Pathology at UC Davis. "NEXUS CGH has allowed us to move from raw data into exploring CNV's and associated genes in a matter of few hours whereas this process took months to complete with other commercial or academic packages."
Dr. Anjene Addington, Child Psychiatry Branch, NIMH, NIH said, "With Nexus CGH, we are able to quickly and easily identify key regions of interest and jump straight to relevant statistical tests and bioinformatics tools, making the whole process more efficient."
Nexus CGH version 2 is the only commercial package offering unique features such as statistical significance test of aberration frequencies, automatic identification of regions of significant statistical difference between sample groups, clustering samples based on genomic profile, and much more.
"We have received an overwhelmingly positive reception to Nexus CGH from leading research institutions including UCSF, Johns Hopkins, UCLA, NIH, The Norwegian Radium Hospital, UCD, Duke, City of Hope, Harvard, and Dundee University," said Dr. Soheil Shams, CEO, BioDiscovery, Inc. "Nexus CGH version 2 enables scientists to convert mountains of copy number data into actionable knowledge in a matter of minutes."
BioDiscovery is a leader in the development of microarray advanced bioinformatics software and services that enable its customers to revolutionize drug discovery and diagnostics by efficiently managing, integrating, and analyzing data generated using high-throughput microarray technology. Contact us: 310-414-8100 or http://www.biodiscovery.com.
|SOURCE BioDiscovery, Inc.|
Copyright©2007 PR Newswire.
All rights reserved